From: Pharmacogenetics of antidepressant response: An update
Reference | Gene | Drug | Sample | Outcome measure(s) | Results | p-value |
---|---|---|---|---|---|---|
[17] | CYP2B6 | Bupropion | 291 patients treated with bupropion or placebo (12 weeks) | Abstinence rates | Individuals with the DRD2-Taq1 A2/A2 genotype demonstrated a higher odds ratio of abstinence only if they possessed the CYP2B6 1459 T/Tor C/T genotypes | p <0.01 |
[18] | CYP2D6 and CYP2CI9 | Amitriptyline | 202 post-mortem cases of patients receiving treatment with amitriptyline | Plasma concentration of amitriptyline and of six metabolites | Positive correlations between trans-hydroxylated metabolites and number of functional copies of CYP2D6 and between demethylated metabolites and the number of functional copies of CYP2CI9 | 0.026 <p <0.001 |
[19] | CYP2D6 | Venlafaxine | 100 patients | CGI UKU | A PM phenotype of CYP2D6 increases the risk of side effects, especially when O-desmethylvenlafaxine/ venlafaxine ratios below 0.3 | p <0.005 |
[20] | CYP2D6 | Fluvoxamine | 100 depressed outpatients | Clinical assessment of GI side effects | CYP2D6 PM with G/G 5-HT2A A-1438G polymorphism had 4.242-fold higher risk of GI side effects and PM with the A/G genotype had a 4.147-fold higher risk of GI side effects | p = 0.009 and p = 0.004 |
[21] | CYP2C9, 2CI9 and 2D6 | Amitriptyline, citalopram, clomipramine, doxepin, fluvoxamine, mirtazapine, paroxetine, sertraline and venlafaxine | 136 depressed Caucasian patients | HAMD CGI UKU | Significant influence of the CYP2D6 genotype, minor influence of the CYP2C19 genotype and no influence of the CYP2C9 genotype on plasma antidepressant concentrations. No association between plasma concentration and antidepressant response | p <0.001 |
[22] | CYP2D6 | Various | 200 outpatients enrolled, 28 were eligible for analysis | Presence of adverse effects | PM associated with more side effects; UM genotype is associated with non-responder phenotype | p <0.001 and p = 0.0012 |